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Structured Summary
Background—Adherence to antiretroviral therapy (ART) is a necessary condition to the 
improvement of HIV patient health and public health through ART. This study sought to determine 
the comparative effectiveness of different interventions for improving ART adherence among HIV-
infected persons living in Africa.
Methods—We searched for randomized trials that evaluated an intervention to promote 
antiretroviral adherence within Africa. We created a network of the differing interventions by 
pooling the published and individual patient data for comparable treatments and comparing them 
across the individual interventions using Bayesian network meta-analyses. Outcomes included 
self-reported adherence and viral suppression.
Findings—We obtained data on 14 randomized controlled trials, involving 7,110 patients. 
Interventions included daily and weekly short message service (SMS) messaging, calendars, peer 
supporters, alarms, counseling, and basic and enhanced standard of care (SOC). For self-reported 
adherence, we found distinguishable improvement in adherence compared to SOC with enhanced 
SOC (odds ratio [OR]: 1.46, 95% credibility interval [CrI]: 1.06–1.98), weekly SMS messages 
(OR:1.65; 95% CrI: 1.25–2.18), counseling and SMS combined (OR:2.07; 95% CrI: 1.22–3.53), 
and treatment supporters (OR:1.83; 95% CrI:1.36–2.45). We found no compelling evidence for the 
remaining interventions. Results were similar when using viral suppression as an outcome, 
although the network of evidence was sparser. Treatment supporters with enhanced SOC (OR:
1.46; 95% CrI: 1.09–1.97) and weekly SMS messages (OR:1.55; 95% CrI: 1.00–2.39) were 
significantly superior to basic SOC.
Interpretation—Several recommendations for improving adherence are unsupported by the 
available evidence. These findings should influence guidance documents on improving ART 
adherence in poor settings.
Introduction
Antiretroviral therapy (ART) has clinical and public health benefits by decreasing morbidity 
and mortality of HIV-infected individuals as well as HIV transmission to sex partners.1 
Many patients experience difficulties in taking their ART at some time in their life and may 
take it only sporadically or take drug holidays.2 There are many possible reasons for not 
taking ART, including a myriad of social, personal and structural factors.3, 4 Promoting 
adherence to ART is considered one of the chief public health concerns for populations 
living with HIV infection.5
Mills et al. Page 2
Lancet HIV. Author manuscript; available in PMC 2016 November 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Despite the importance of achieving and maintaining high rates of ART adherence, few 
interventions have proved successful among those experiencing difficulties.6, 7 In Africa, 
where most people with HIV infection reside, there are specific social, structural or health 
system-related barriers that are particularly prevalent including food insecurity, stigma, 
supply chain interruptions, and a lack of human health resources.8 Previous systematic 
reviews have identified potentially effective interventions, but have not evaluated their 
effectiveness in a statistical way.7, 9, 10
The past decade has seen important progress in the field of evidence synthesis, particularly 
with the popularization of network meta-analysis (NMA).11–14 In traditional meta-analysis, 
all included studies compare the same intervention with the same comparator. NMA extends 
this concept by including multiple pairwise comparisons across a range of interventions and 
provides estimates of relative treatment effects on multiple treatment comparisons for 
comparative effectiveness purposes based on direct and/or indirect evidence. Here, direct 
evidence for the effect of treatment B vs. A would correspond to the evidence familiar to us 
in pairwise meta-analysis, combining all head to head comparisons. Indirect evidence 
corresponds to all common comparisons of B vs. A through common comparators, such as 
standard of care. Thus, NMA allows for inference between two interventions even in the 
absence of head-to-head evidence. The conditions required for conducting these analyses 
resemble those of traditional meta-analysis, however, they require that direct and indirect 
evidence be in agreement, a condition called consistency. Therefore, we aimed to evaluate 
what ART adherence interventions have been conducted in the African setting. We used a 
NMA approach to draw from both direct and indirect evidence from randomized trials.
METHODS
This study has been designed and reported according to the pending Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) extension to network meta-
analyses.15 The protocol for this study is available from the authors upon request.
Selection Criteria
The populations, interventions, comparisons, outcomes and study designs considered for 
review are listed in Box 1. All RCTs must have included an intervention targeted to increase 
ART adherence, and targeted to increase ART adherence over a minimum of a 3-month 
period, and report ART adherence as an outcome. We restricted trials to African countries to 
avoid issues of dissimilarity that arise from variations in HIV risk groups.
Search Strategy
We conducted a systematic search of the medical literature for relevant randomized clinical 
trials that described interventions to improve adherence to ART among HIV-positive 
patients, using terms for “HIV”, “ART”, “adherence” and “Africa”. The search was 
conducted using the following electronic databases: AMED, CINAHL, EMBASE, 
MEDLINE (via PubMed), and Clinicaltrials.gov from inception to October 2014. The 
complete search strategy used to identify studies is available in the web appendix. Two 
investigators (KM, ML) reviewed all abstracts and full-text articles. We contacted all study 
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authors and requested the individual data on patients achieving adherence and viral 
suppression. We did not set any restriction based on publication date and included all studies 
available as of October 2014.
Data extraction and Variable Definitions
Using a standard data sheet, we extracted the following data from articles that met the 
inclusion criteria: 1) trial duration; 2) trial location; 3) year of publication; 4) rate of loss to 
follow-up; 5) ART experience; 6) proportion of women; 7) median age; 8) sample size 
within each treatment arm; 9) treatment within each arm; 10) count of participants attaining 
adherence in each arm; 11) the measures of adherence used; 12) the number retained 
throughout the study. When data were unavailable or only partial, we requested data directly 
from authors. Data extraction from eligible studies was done independently and in duplicate.
We grouped treatment arms using the following categories: 1) standard of care (SOC); 2) 
enhanced standard of care (eSOC); 3) alarm; 4) eSOC + alarm; 5) eSOC + calendar; 6) daily 
SMS; 7) weekly SMS; 8) eSOC + weekly SMS; 9) eSOC + treatment supporter; 10) SOC + 
treatment supporter. Definitions for treatment groupings are provided in Box 1. In brief, 
SOC consisted of regular ART pick-ups including consultations with physician or 
pharmacist. In some cases adherence counseling was reported as part of SOC, and in others 
as a specific intervention, particularly when counselors were involved. We did not 
differentiate such cases and considered interventions that included adherence counseling in 
addition to SOC, either directly from the health practitioner or from adherence counselors, to 
be eSOC. Finally, we did not differentiate treatment supporters that assisted in directly 
observed treatment (DOT) and those who provided other assistance.
The primary outcome was adherence as defined by the proportion of patients in each RCT 
arm meeting the trial-defined adherence criteria. Adherence was measured using the 
percentage of pills taken with various cut-off values and when multiple measures were 
reported they were favored in the following order: 95%, 90%, 80%, and 100%. We chose to 
place the 100% cut-off last in our order because it over-estimates poor adherence.16 The 
proportion of patients achieving viral suppression was collected as a secondary outcome. All 
outcomes were extracted at the end of study period.
Data Synthesis and Analysis
To inform comparative effectiveness between all interventions, we conducted a Bayesian 
network meta-analysis (NMA) using all ten intervention types.17 This method provides 
better comparative evidence than pair-wise meta-analysis because it combines direct (i.e., 
head-to-head comparisons) and indirect evidence (comparisons across a common 
comparator) and in doing so increases the power of statistical comparisons while allowing 
for inferences of comparative effects between interventions that have not been compared 
head-to-head.13, 18 In estimating the efficacy parameters using Markov chain Monte Carlo 
methods, we used a burn-in of 20,000 iterations and 40,000 iterations for estimation. 
Convergence was assessed used Gelman-Rubin diagnostics. Priors were normally 
distributed, centered at zero, with large variance for all parameters except the probability of 
adherence and viral suppression, which both used a binomial prior distribution.
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We performed edge-splitting to assess the consistency of direct and indirect evidence for 
interventions for which both types of information was available.19 We assessed the deviance 
information criterion (DIC) as a measure of model fit that penalizes for model complexity.20 
We modeled comparative log odds ratios using the conventional logistic regression NMA 
setup.17 All results for the network meta-analysis are reported as posterior medians with 
corresponding 95% credibility intervals (CrIs), the Bayesian analog of classical confidence 
intervals. Sensitivity analyses included period of trial follow-up and choices of adherence 
thresholds for measurement.
All analyses were conducted using WinBUGS version 1.4 (Medical Research Council 
Biostatistics Unit, Cambridge) and R version 3.0.1 (http://www.r-project.org/).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
RESULTS
We identified 151 relevant abstracts (Figure 1). Of these, 118 publications did not meet our 
inclusion criteria. Of the 33 further reviewed manuscripts, we excluded 20 publications (as 
not RCTs [n=12],21–32 not adherence interventions [n=1],33 did not report adherence after 3 
months [n=1],34 irrelevant interventions [n=2],35, 36 outcome not reported [n=1],37 cluster 
study design [n=1],38 paediatric population [n=1],39 or sub-study of another included trial 
[n=1]40); these studies are listed in Appendix 2. We included the remaining 13 publications, 
along with an additional poster provided following the search. Together, these described 14 
RCTs in our analyses (Table 1).38, 39, 41–53 Individual level data were available for 9 of the 
RCTs.
Adherence
Our primary network includes data from 13 studies (n = 5,310), comprising 30 treatment 
arms. Figure 2 represents the network of evidence for ART adherence interventions 
contained in the included studies. Nodes represent each included intervention; numbers on 
each edge represent the number of corresponding trials. Follow-up time for adherence 
outcomes varied from 17 to 192 weeks. Various measures were used to report adherence. 
The most common measure reported was the proportion of patients in each arm with at least 
95% adherence by self-report; ten studies reported this operationalization.41–46, 48, 51–53 
Four studies reported the proportion of patients with no missed dose or 100% 
adherence,41, 46, 47, 53 and two reported the proportion with at least 90% adherence.49, 50
In order to assess consistency across the network, we calculated direct and indirect evidence 
for each comparison for which both types of evidence were available. The results of this 
edge-splitting exercise are presented in Appendix 3. Results were consistent between direct 
and indirect evidence, suggesting that conditions required for these analyses were met.
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Table 2 presents odds ratios (OR) and 95% credibility intervals (CrI) for all pairwise 
comparisons of adherence interventions. Enhanced SOC performed better than basic SOC. 
Weekly SMS (with or without eSOC) was associated with better adherence than SOC alone. 
The combination of eSOC with a treatment supporter performed better than SOC, eSOC, or 
the alarm alone. Weekly SMS (without eSOC) was associated with higher adherence than 
daily SMS (OR 1.56, 95% CrI 1.01–2.40); the difference between weekly SMS with eSOC 
compared to daily SMS was not statistically or operationally important. No other pairs of 
adherence interventions were found to be statistically different. Further inference can be 
drawn from table 2. The combination of the effect estimates for eSOC and weekly SMS was 
2.41, suggesting an additive effect of eSOC and weekly SMS.
We additionally examined the follow-up time and choice of adherence measurement as 
potential sources of heterogeneity through sub-analyses. Neither factor was found to 
influence the comparative efficacy measurements. As a sensitivity analysis for the adherence 
outcome, an additional NMA was conducted using the number remaining in the study (per-
protocol) rather than intention to treat; the results are given in Appendix 4. Comparisons of 
eSOC+alarm versus SOC, eSOC, and alarm alone were all found to be statistically 
significant in the per-protocol analysis, suggesting differential loss-to-follow up among these 
treatment arms. Appendix 5 displays the pairwise pooled estimates compared with the 
network estimates.
Viral suppression
Our secondary network meta-analysis included data from 13 treatment arms in six 
studies41, 44, 48, 51, 52, 54 (N = 2,738). The network of evidence contained in these studies is 
shown in Figure 3. Six interventions were included in the studies with available viral 
suppression data: SOC, eSOC, alarm, weekly SMS, eSOC+treatment supporter, and SOC
+treatment supporter. For studies where multiple time points were reported, the same time 
points were selected as in the adherence analysis where possible. Four studies reported the 
number of patients who had achieved plasma HIV RNA suppression (< 400 copies/
mL),44, 51, 52, 54 one study reported the number of patients on-study with viral failure 
defined as ≥400 copies/mL,41, 54 and one study reported the number of patients on-study 
with viral failure defined as ≥5,000 copies/mL.42 We modeled viral suppression with an on-
study analysis that treating measured lack of failure as equal to suppression regardless of the 
cutoff point.
As with adherence, we performed edge-splitting in order to assess consistency between 
direct and indirect evidence across the network. The results are shown in Appendix 6; results 
were reasonably consistent, although there was a greater (but still non-significant) OR found 
for eSOC vs SOC with direct evidence than by indirect evidence alone.
Table 3 presents ORs and 95% CrI for viral suppression for all pairwise comparisons of 
interventions with available viral suppression data. Both weekly SMS (OR: 1.55; 95% CrI: 
1.01–2.38) and eSOC+treatment supporter (OR: 1.46; 95% CrI: 1.09–1.97) were associated 
with higher suppression rates than SOC, or SOC+treatment supporter. No other pairs of 
adherence interventions were found to be different with respect to viral suppression.
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DISCUSSION
Our analysis examined all RCTs conducted to evaluate interventions to promote adherence 
to antiretroviral therapy in Africa. We found compelling evidence that enhanced standard of 
care improved patient adherence. This was further improved when combined with weekly 
SMS messages and treatment supporters. In fact, the combination of enhanced standard of 
care, a cognitive intervention, and weekly SMS messaging, a behavioral intervention, 
appeared to be additive in nature, a novel finding that could not be tested in the individual 
studies in the current evidence base. Our findings also provide evidence that there is 
insufficient evidence to support alarms, daily SMS messages, and calendars. These findings 
are at odds with some previous reports and meta-analyses and the difference may be partly 
explained by the analytical approach we used.10, 55 Our study found a large treatment benefit 
for weekly SMS messages but not for daily SMS messages. It is possible that there is a dose-
effect wherein less is more as, supportive SMS messages may become a reminder when too 
frequent, and reminders do not appear to support adherence.56
Our findings have operational and clinical implications. For example, we found a large, 
additive treatment benefit of adding weekly SMS messages to enhanced standard of care. 
Our study suggests that combining cognitive and behavioural interventions could maximize 
the intervention efficacy. Although weekly SMS messaging is a relatively low cost 
intervention, it requires that patients have access to a cell phone and can receive SMS 
messages confidentially.57 Given the high penetration of mobile technology in low-income 
settings such as sub-Saharan Africa, India, etc. our findings may have global relevance and 
implications. Nonetheless, there remain features of the weekly SMS messaging intervention 
that need be further researched and determined by program managers, such as whether 
patients will be able to respond to the messages and reach a care provider (“two way” 
messages) or not (“one way”), and what content should be sent.58 The trials considered in 
this study differed in this regard.
Similarly, we found a large treatment effect of a treatment supporter in combination with 
enhanced standard of care. However, this intervention would be inappropriate where 
confiding one’s HIV status to another person is not possible.48 Our finding that treatment 
supporters importantly increase adherence is at odds with some reviews examining treatment 
supporters and directly observed therapy.55, 59 Other reviews have included populations with 
competing mental health concerns and have used standard meta-analysis approaches. The 
use of a network meta-analysis allows for greater power and greater precision in the analysis 
and this appears to explain why our findings are significant and other’s findings are not.60 
Prior work has documented the feasibility, acceptability, and potential efficacy of treatment 
supporters as a community-based intervention (i.e. wide spread use of this method 
throughout the community).48, 61, 62
Across HIV programs, treatment supporters can be defined in several ways and this has 
created a debate within the implementation field as to what extent they should be promoted. 
Treatment supporters range from paid employees, such as accompagnateurs in Partners in 
Health projects, to unpaid family and friends in other programs.55 Similarly, treatment 
supporters may offer assistance that ranges from emotional support and reminding patients 
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to adhere to therapy or more intensively offer services that may include directly observed 
therapy (DOT) and clinical monitoring. The evidence to support DOT is not convincing,55 
but the evidence for social support that may include adherence discussions and reminders is 
much more broadly accepted. It is unlikely that this analysis will settle the issue.
There are several strengths and limitations to consider in our analysis. Strengths include our 
extensive search, communication with trialists, and the statistical approach we used. We held 
meetings of those working in the field to identify any additional trials and received 
individual patient level data where possible. Our statistical approach allows for greater 
power than standard meta-analysis as it incorporates data from both indirect and indirect 
evidence (see Appendix 4). Limitations of our review to generalizability include the lack of 
available data in specific populations such as HIV-infected children, adolescents, pregnant 
women, prisoners, MSM etc. that could be inserted into the network. We found a low 
number of studies for each individual intervention and so further confirmatory RCTs are 
warranted. We considered including studies from more developed settings, however, given 
that the HIV epidemic in Africa is substantially different than in other continents (in terms 
of a generalized epidemic) and that most RCTs in other settings have been directed at 
individuals with competing mental health concerns (e.g. addictions) or marginalized persons 
(e.g. homeless, youth, etc.), we believe that restricting the analysis to Africa is necessary to 
meet the conditions required for the methodology employed for our analyses.
An important limitation to our study pertains to treatment definitions. As opposed to drugs, 
these behavioral and cognitive interventions varied across studies. This is especially true of 
eSOC, defined as SOC with an educational component, because the education component 
varied according to content and whether it was delivered in-group or one-on-one. 
Nonetheless, statistical heterogeneity was moderate, suggesting that this was a minimal 
threat. Limitations to external validity include the exclusion of pediatric populations from 
the network, but this was by design given that adherence among children is typically a 
caregiver issue rather than patient-motivated. In addition, we considered various definitions 
of adherence and viral failure as equivalent. We considered self-reported adherence and 
more objective forms (such as medication event monitoring systems [MEMS]) as equivalent. 
However, self-report may over-estimate adherence.63 There were an insufficient number of 
studies to assess this using a sensitivity analysis. We included only RCTs and it is possible 
that there are other interventions that have been conducted at the program level in a non-
research manner, that also have important treatment benefits. We are aware that interventions 
to promote retention in programs differ across and within countries and we acknowledge that 
some programs may use different adherence strategies also.64 Finally, we considered the 
RCT period as equivalent across studies and conducted a sensitivity analysis examining for 
duration of follow-up. Although we did not identify time as an effect modifier, it is likely 
that adherence will wane with any intervention over the long term.65, 66
Network meta-analysis should only be considered as valid as the individual comparisons 
within a network. In our network, several of the nodes in the network are informed by just 
one or two trials and at most by five trials. In general, the more trials in a comparison, the 
greater the power to detect treatment effects.18, 67 Although we cannot add trials to our 
network, because no other trials exist, we can assess whether the comparisons are believable 
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by assessing the transitivity of direct versus indirect evidence.68 When we assessed pairwise 
estimates versus network estimates we found no evidence of inconsistency between the 
direct and indirect evidence. This increases our confidence that the network is sufficiently 
robust that the findings are unlikely to be spurious.68 As further evidence accumulates, this 
will further strengthen inferences from the network evaluation.
In conclusion, this study provides strong inferences that a standard of care that includes 
patient counseling on adherence, SMS messaging, and treatment supporters can improve 
adherence for patients residing in Africa. As the provision of ART in Africa becomes more 
long-term, sustainable efforts to promote adherence will be required. Future research should 
consider evaluating other novel adherence interventions individually or in combination, not 
only in adult populations but also in selected vulnerable populations where there is a large 
knowledge gap such as children, adolescents, and pregnant women, as well as assess the 
cost-effectiveness to inform policy-makers, clinicians and program managers.
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Appendix 1
Search terms
(Human immunodeficiency virus OR HIV OR Acquired Immunodeficiency Syndrome OR 
AIDS OR HIV Infection[MeSH])
AND
(antiretroviral OR anti-retroviral OR antiretroviral therapy OR highly active antiretroviral 
therapy OR HAART OR Anti-HIV Agents OR Agents, Anti-HIV[MeSH])
AND
(patient compliance OR client compliance OR participant compliance OR adherence OR 
Adherence, Medication[MeSH] OR Therapy, Directly Observed[MeSH] OR Compliance, 
Patient[MeSH])
AND
(Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon 
OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo OR Cote 
d'Ivoire OR Cote OR Democratic Republic of the Congo OR Equatorial Guinea OR Eritrea 
OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya 
OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius 
OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome and 
Principe OR Sao Tome OR Principe OR Senegal OR Seychelles OR Sierra Leone OR 
Somalia OR South Africa OR Swaziland OR Togo OR Uganda OR United Republic of 
Tanzania OR Tanzania OR Zambia OR Zimbabwe OR sub-saharan Africa OR subsaharan 
africa OR africa, sub-saharan OR Africa OR East Africa OR West Africa OR Southern 
Africa)
Appendix 2
List of studies excluded following full-text review
Study Exclusion rationale
Byron, 200830 Not an RCT
Cantrell, 200833 Not an adherence intervention
Holstad, 201235 Not an appropriate control group
Idoko, 200721 Not an RCT
Igumbor, 201131 Not an RCT
Kabore, 201022 Not an RCT
Kiweewa, 201336 Endonodal trial
Mansoor, 200634 Follow-up less than 3 months
Munyao, 201040 Substudy of Sarna51
Pienaar, 200625 Not an RCT
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Study Exclusion rationale
Pirkle, 200929 Not an RCT
Rich, 201232 Not an RCT
Roux, 200428 Not an RCT
Sherr, 201023 Not an RCT
Stubbs, 200924 Not an RCT
Thurman, 201026 Not an RCT
Torpey, 200827 Not an RCT
Van Loggerenberg, 201037 Adherence outcome not reported
Legend: endonodal refers to a trial that compares a form of an intervention to another form of the same intervention (eg. 
dosing studies).
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Appendix 5
Results of pairwise meta-analyses of comparisons of adherence interventions
Pairwise comparison Network meta-analysis
Comparison N Arms OR (95% CI) OR (95% CI)
Enhanced SOC vs SOC 2 1.24 (0.76–2.03) 1.46 (1.06–1.98)
Alarm vs SOC 1 0.85 (0.49–1.48) 1.00 (0.60–1.67)
Enhanced SOC + alarm vs SOC 1 1.33 (0.76–2.32) 1.57 (0.94–2.62)
Daily SMS vs SOC 1 1.89 (0.67–1.75) 1.06 (0.68–1.64)
Weekly SMS vs SOC 2 1.65 (1.15–2.28) 1.65 (1.25–2.18)
Enhanced SOC + weekly SMS vs SOC 1 2.64 (1.13–6.16) 2.07 (1.22–3.53)
Enhanced SOC + treatment supporter vs SOC 2 2.58 (1.71–3.89) 1.83 (1.36–2.45)
Alarm vs enhanced SOC 1 0.82 (0.47–1.43) 0.69 (0.41–1.14)
Enhanced SOC + alarm vs enhanced SOC 1 1.27 (0.73–2.23) 1.26 (1.00–1.58)
Enhanced SOC + calendar vs enhanced SOC 1 1.08 (0.52–2.25) 1.25 (0.67–2.57)
Enhanced SOC + weekly SMS vs enhanced SOC 1 1.24 (0.68–2.26) 1.42 (0.86–2.35)
Enhanced SOC + treatment supporter vs enhanced 
SOC
5 1.13 (0.88–1.46) 1.26 (1.00–1.58)
Enhanced SOC + alarm vs alarm 1 1.55 (0.89–2.72) 1.56 (0.89–2.74)
Enhanced SOC + treatment supporter vs enhanced 
SOC +
calendar
1 1.21 (0.33–4.38) 1.01 (0.48–1.93)
Weekly SMS vs daily SMS 1 1.59 (1.00–2.53) 1.56 (1.01–2.40)
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Research in Context Panel
Systematic Review
We conducted a systematic search of the medical literature for relevant randomized 
clinical trials that described interventions to improve adherence to ART among HIV-
positive patients, using terms for “HIV”, “ART”, “adherence” and “Africa”. The search 
was conducted using the following electronic databases: AMED, CINAHL, EMBASE, 
MEDLINE (via PubMed), and Clinicaltrials.gov from inception to December 2013. We 
identified 14 RCTs for our analysis that met our study’s inclusion/exclusion criteria.
Interpretation
We found compelling evidence that enhanced standard of care improved patient 
adherence. This was further improved when combined with weekly SMS messages and 
treatment supporters. As the provision of ART in Africa becomes increasingly available, 
effective interventions to promote adherence will be necessary to generate sustainable 
ART delivery.
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Box 1
Population, interventions, comparisons, outcomes and study design (PICOS) criteria for 
study inclusion.
Criteria Definition
Population Adult HIV+ patients on ART in Africa
Interventions Any intervention to improve adherence to ART
Comparisons Standard of care or another intervention to improve adherence to ART
Outcomes Any measurement of adherence to ART
Study Design RCT with minimum 3 months of follow-up
Treatment definitions used for categorization of interventions in the network meta-analysis
Criteria Definition
Standard of Care
(SOC)
Usual standard of care
Enhanced SOC
(eSOC)
Usual standard of care, plus intensified adherence counseling
Alarm Participants received a pocket alarm device which they were to carry around at all 
times; this device was programmed to beep and flash twice a day to remind 
patients to take their medication
eSOC + alarm Enhanced SOC plus the pocket alarm device as described above
eSOC + calendar In addition to enhanced SOC, patients were given a treatment calendar containing 
educational messages about ART and adherence; patients were to record when 
they took their medication in the calendar
Daily SMS Daily text message sent to the patient’s cell phone (their own or one provided by 
the study) – with or without ability for patient to respond to care provider
Weekly SMS Weekly text message sent to the patient’s cell phone (their own or one provided by 
the study) – with or without ability for patient to respond to care provider
eSOC + weekly SMS Weekly text message sent to the patient’s cell phone (their own or one provided by 
the study) in addition to enhanced SOC
eSOC + treatment
supporter
Treatment supporter (chosen by individual or assigned by clinic) in addition to 
enhanced SOC
SOC + treatment
supporter
Treatment supporter (chosen by individual or assigned by clinic) in addition to 
SOC
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Figure 1. 
Flow diagram of study selection.
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Figure 2. 
Network diagram for randomized clinical trials evaluating interventions seeking to improve 
ART adherence among HIV-positive patients
Legend. Nodes represent the individual or combined interventions. Lines between the nodes 
represent where direct (head-to-head) RCTs have been conducted. The numbers within those 
lines indicate the number of RCTs that have been conducted.
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Figure 3. 
Network diagram for randomized clinical trials evaluating viral suppression between 
interventions seeking to improve ART adherence among HIV-positive patients.
Legend. Nodes represent the individual or combined interventions. Lines between the nodes 
represent where direct (head-to-head) RCTs have been conducted. The numbers within those 
lines indicate the number of RCTs that have been conducted.
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